We are live on ! Find out more
NMRA icon

Neumora Therapeutics
NMRA

98 hedge funds and large institutions have $41.1M invested in Neumora Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 28 increasing their positions, 28 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

165% more call options, than puts

Call options by funds: $143K | Put options by funds: $54K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 28

5.63% less ownership

Funds ownership: 40.27% → 34.64% (-5.6%)

15% less funds holding

Funds holding: 115 → 98 (-17)

37% less capital invested

Capital invested by funds: $65.2M → $41.1M (-$24.1M)

40% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 40

Holders
98
Holders Change
-17
Holders Change %
-14.78%
% of All Funds
1.29%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
28
Reduced
28
Closed
40
Calls
$143K
Puts
$54K
Net Calls
+$89K
Net Calls Change
-$63K

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
+$798K
2
GCP
GSA Capital Partners
United Kingdom
+$543K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$491K
4
Millennium Management
Millennium Management
New York
+$389K
5
AC
AlphaCore Capital
California
+$256K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$2.63M
2
UBS Group
UBS Group
Switzerland
-$1.86M
3
State Street
State Street
Massachusetts
-$1.04M
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$803K
5
Bank of America
Bank of America
North Carolina
-$604K
Name Holding Trade Value Shares
Change 		Change in
Stake
SoftBank Group
1
SoftBank Group
Japan
$4.8M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.49M -$426K -562,134 -11%
MCMU
3
MIC Capital Management (UK)
United Kingdom
$3.27M – – –
SL
4
Siren LLC
Connecticut
$3.2M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$2.57M +$4.81K +6,350 +0.2%
WT
6
Wellcome Trust
United Kingdom
$2.43M – – –
BlackRock
7
BlackRock
New York
$2.11M -$2.63M -3,472,424 -55%
IC
8
Iconiq Capital
California
$1.88M – – –
LC
9
Lunate Capital
United Arab Emirates
$1.56M – – –
T. Rowe Price Investment Management
10
T. Rowe Price Investment Management
Maryland
$1.54M – – –
JJ
11
Johnson & Johnson
New Jersey
$1.4M – – –
Renaissance Technologies
12
Renaissance Technologies
New York
$1.05M +$133K +174,997 +14%
TCM
13
Tang Capital Management
California
$1.03M – – –
Millennium Management
14
Millennium Management
New York
$903K +$389K +513,066 +71%
Two Sigma Advisers
15
Two Sigma Advisers
New York
$901K +$798K +1,052,900 +598%
BBA
16
Baker Bros. Advisors
New York
$759K – – –
Geode Capital Management
17
Geode Capital Management
Massachusetts
$673K -$803K -1,059,487 -54%
GCP
18
GSA Capital Partners
United Kingdom
$663K +$543K +717,030 +384%
AQR Capital Management
19
AQR Capital Management
Connecticut
$569K +$237K +313,469 +68%
Acadian Asset Management
20
Acadian Asset Management
Massachusetts
$487K +$491K +648,411 +3,296%
UBS Group
21
UBS Group
Switzerland
$477K -$1.86M -2,455,852 -79%
Two Sigma Investments
22
Two Sigma Investments
New York
$431K +$238K +314,018 +114%
Goldman Sachs
23
Goldman Sachs
New York
$368K -$80K -105,615 -17%
GCM
24
Graham Capital Management
Connecticut
$342K -$528K -696,634 -60%
Charles Schwab
25
Charles Schwab
California
$325K -$114K -150,331 -25%
1
2 3 4 5

NMRA Hedge Fund Activity: Q2 2025 in Review

98 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Neumora Therapeutics (NMRA) for Q2 2025, worth a combined $41.1M — down 37% from $65.2M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of NMRA and 24 opened new positions — a net loss of 16 holders — while 28 trimmed existing stakes and 28 added.

The largest buyer was Two Sigma Advisers, adding an estimated $798K. The largest seller was BlackRock, cutting an estimated $2.63M.

  • 98 institutional investors held Neumora Therapeutics (NMRA) as of Q2 2025, down from 115 in Q1 2025.
  • Funds reported $41.1M of Neumora Therapeutics stock for Q2 2025, down 37% quarter-over-quarter.
  • 24 funds opened new Neumora Therapeutics positions in Q2 2025 and 40 closed out, a net change of -16 holders.
  • The largest Neumora Therapeutics buyer in Q2 2025 was Two Sigma Advisers, an estimated $798K added.
  • The largest Neumora Therapeutics seller in Q2 2025 was BlackRock, an estimated $2.63M sold.

Based on aggregated 13F filings for Q2 2025.